ANS-05

N/A

Report date: 2025/10/20 14:18:44
NME

Base Information

Drug NameANS-05
Drug Alias NameANS-05
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHER2 exon 20 insert mutations inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2HER2 exon 20 insert mutations
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesBeijing Avistone Pharmaceuticals Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Avistone Pharmaceuticals Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A